BiomX Inc. (PHGE)

Biological Products, (No Diagnostic Substances) · market cap $63M · as of 2026-07-16

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

BiomX Inc. (PHGE) is a micro-cap biotech with a market cap of approximately $2M and a share price of ~$0.21, focused on phage-based therapeutics. Its lead asset, BX004-A, is in Phase 2 development for chronic Pseudomonas aeruginosa infection. The company has approximately $1.2M in cash, representing roughly 0.6 months of runway, placing it in acute financial distress.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
BX004-A	Phase 2	Chronic Pseudomonas Aeruginosa Infection
BX004	Phase 2	Chronic Pseudomonas Aeruginosa Infection

Price & technical context

3-month

+25.3%

6-month

-89.3%

12-month

-96.0%

52-wk range

$0.16–$11.97

vs 50-day MA

-54.7%

vs 200-day MA

-81.5%

Realized vol

297.5%

Max drawdown

-99.3%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for PHGE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.